Apoptosis in prostatic adenocarcinoma following complete androgen ablation.
OBJECTIVE
To analyze the cell death phenomenon in prostate cancer following complete androgen ablation.


METHODS
The frequency and location of apoptotic bodies (ABs) were evaluated in haematoxylin and eosin stained sections of radical prostatectomy specimens from patients with invasive prostatic adenocarcinoma treated with neo-adjuvant endocrine combination therapy for 3 months before surgery. The results were compared with an untreated age- and stage-matched control group.


RESULTS
Both in treated and untreated prostate tissue the AB frequency increased from normal prostate, through prostatic intraepithelial neoplasia, up to prostatic adenocarcinoma. The main location was in the cell layers adjacent to the stroma, their frequency decreasing towards the lumen. The frequency of ABs was higher in the treated prostate glands than in the untreated groups. The relative increase of the AB frequency in treated carcinomas as compared with untreated ones was lowest in tumours with a solid pattern, intermediate in the cribriform, and highest in the acinar pattern.


CONCLUSIONS
Complete androgen ablation induces involution of prostate tissue mainly through the enhancement of apoptosis. This type of cell death is thought to play a major role and might be linked to specific changes in signal transduction mechanisms in response to hormonal withdrawal.
Montironi
R
R
Institute of Pathological Anatomy and Histopathology, University of Ancona, Italy. r.montironi@popcsi.unian.it
Pomante
R
R
Diamanti
L
L
Magi-Galluzzi
C
C
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D017209:Apoptosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*
D000726:Androgen Antagonists